---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-027668"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T05:05:20.730904+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zai Lab CMO Dr. Harald Reinhart to retire; Dr. Rafael Amado to lead all Global R&D

## Summary
- Dr. Harald Reinhart, President, Head of Global Development (NSAiID), retiring effective June 30, 2024.
- Reinhart will remain as a senior advisor; no disagreements led to his retirement.
- Dr. Rafael Amado expands role to President, Head of Global R&D upon Reinhart's retirement.
- Amado previously President of Global Oncology R&D; now oversees all therapy areas.
- CEO Samantha Du noted Reinhart built strong NSAiID team for continued growth under Amado.

## SEC filing metadata
- accession: 0001628280-24-027668
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828024027668/0001628280-24-027668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828024027668/zlab-20240611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-027668
- JSON: https://secwatch.observer/filing/0001628280-24-027668.json
- Plain text: https://secwatch.observer/filing/0001628280-24-027668.txt

## Source-grounded claims
- claim_id: 39ea1cade4
  claim: Harald Reinhart retired as President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases at Zai Lab Ltd.
  evidence_excerpt: On June 11, 2024 , Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704292/000162828024027668/0001628280-24-027668-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.